Vedolizumab blocks alpha 4 beta 7 integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis

Besendorf L, Müller T, Geppert CI, Schneider I, Mühl L, Atreya I, Vitali F, Atreya R, Neurath M, Zundler S (2022)


Publication Type: Journal article

Publication year: 2022

Journal

Book Volume: 15

DOI: 10.1177/17562848221098899

Abstract

Background: In Crohn's disease and ulcerative colitis, the anti-alpha 4 beta 7 integrin antibody vedolizumab has demonstrated efficacy in phase III trials and has been successfully used under real-world conditions. Occasionally, it has also been used in other forms of inflammatory bowel disease (IBD) such as microscopic colitis (MC). However, the mechanisms of vedolizumab in MC have not been studied to date. Therefore, we aimed to investigate the expression and functional role of gut-homing integrins and in particular alpha 4 beta 7 integrin in a cohort study in MC.

Authors with CRIS profile

How to cite

APA:

Besendorf, L., Müller, T., Geppert, C.-I., Schneider, I., Mühl, L., Atreya, I.,... Zundler, S. (2022). Vedolizumab blocks alpha 4 beta 7 integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis. Therapeutic Advances in Gastroenterology, 15. https://doi.org/10.1177/17562848221098899

MLA:

Besendorf, Laura, et al. "Vedolizumab blocks alpha 4 beta 7 integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis." Therapeutic Advances in Gastroenterology 15 (2022).

BibTeX: Download